FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *  CARUSO JAMES V				<u>(</u>	2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [ CLRB ]								S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC.					3. Date of Earliest Transaction (Month/Day/Year) 01/17/2023							X	X Officer (give title Other (specify below)  President and CEO					
100 CAMPUS DRIVE  (Street)  FLORHAM				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Indix	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
PARK (City)	NJ (State		77932 Zip)															
		Ţ	able I - Nor	-Deriva	tive S	ecuritie	s Acc	uired, D	ispos	sed of	, or Benef	cially Ow	ned					
Date					nsaction h/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed C		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v   A	mount	(A) or (D)		(Instr. 3 and 4)				(111501.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		e and	7. Title and Ar Securities Und Derivative Sec 3 and 4)	derlying	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		ration	Title	Amount or Number of Shares		(Instr. 4)	ioii(s)			
Stock option (right to buy)	\$1.68	01/17/2023		A	A 261,00			(1)	01/17	7/2033	Common Stock 261,0		\$0	261,000		D		

## Explanation of Responses:

1. This option shall vest over a period of three years from the grant date, with 1/3 vesting on the first anniversary of the grant date and the remainder vesting in 24 equal monthly installments over a 24 month period beginning on the first anniversary of the grant date.

/s/ Christina Blakley, Attorney infact for James V. Caruso 01/18/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.